Table 1 -.
Significantly altered canonical pathways and the related altered genes in the different treatment groups.
| Canonical Pathway | Treatment group | |||
|---|---|---|---|---|
| Carb | Carb UV | UV | ||
| Estrogen-mediated S-phase entry | ||||
| p-value | 4.1e−2 | 1.55e−5 | 9.31e−2 | |
| Altered genes (mean fold change) | E2F5 (−1.98) ESR2 (−1.53) |
CCNE2 (+2.32) CDC25A (+1.82) CDKN1A (+1.62) E2F2 (+2.20) E2F5 (−2.58) ESR1 (−2.06) ESR2 (−2.02) MYC (−1.65) |
CDKN1A (+1.45) E2F2 (+2.07) |
|
| NRF2-mediated oxidative stress response | ||||
| p-value | 1.66e−3 | 1.41e−1 | 2.76e−1 | |
| Altered genes (mean fold change) | DNAJB4 (+1.86) DNAJB9 (+2.37) DNAJC3 (+1.56) ENC1 (−1.77) FOS (−1.81) GCLM (+2.18) HERPUD1 (+1.72) HMOX1 (+2.46) |
DNAJB4 (+1.89) DNAJB9 (+2.02) ENC1 (−2.07) FOS (−1.95) GCLM (+2.26) HMOX1 (+2.58) MAP3K5 (−2.68) PRKCA (−1.85) PRKCB (−1.55) PRKCE (−1.98) PRKCH (−1.69) PRKD1 (−1.73) |
MAP3K5 (−1.68) PRKCA (−1.73) PRKCE (−1.82) PRKCH (−1.55) PRKD1 (−1.64) |
|
| GADD45 Signaling | ||||
| p-value | 2.46E−1 | 3.38e−3 | 3.63e−1 | |
| Altered genes (mean fold change) | GADD45B (−2.21) | BRCA1 (+1.28) CCNE2 (+2.32) CDKN1A (+1.62) GADD45B (−1.67) PCNA (+1.62) |
CDKN1A (+1.45) | |
| Cell Cycle: G1/S Checkpoint Regulation | ||||
| p-value | 5.59e−2 | 1.56e−3 | 1.5e−1 | |
| Altered genes (mean fold change) | E2F5 (−1.98) FOXO1 (−1.64) TGFB2 (+2.87) |
CCNE2 (+2.32) CDC25A (+1.82) CDK6 (−1.88) CDKN1A (+1.62) E2F2 (+2.20) E2F5 (−2.58) HDAC9 (−2.95) MDM2 (+1.77) MYC (−1.65) TGFB2 (+2.25) |
CDK6 (−1.79) CDKN1A (+1.45) E2F2 (+2.07) |
|
| Endoplasmic reticulum stress pathway | ||||
| p-value | 3.42e−3 | 3.34e−1 | 3.93e−1 | |
| Altered genes (mean fold change) | DNAJC3 (+1.56) HSPA5 (+1.52) XBP1 (+1.63) |
MAP3K5 (−2.68) XBP1 (+1.55) |
MAP3K5 (−1.68) | |
| Molecular mechanisms of carcinogenesis | ||||
| p-value | 2.95e−1 | 4.26e−3 | 1.31e−2 | |
| Altered genes (mean fold change) | BCL2L11 (−1.41) E2F5 (−1.98) FOS (−1.81) FOXO1 (−1.64) TGFB2 (+2.87) WNT6 (−1.50) |
ARHGEF3 (+1.71) BBC3 (+1.66) BMPR1B (−1.82) BRCA1 (+1.28) CCNE2 (+2.32) CDC25A (+1.82) CDK6 (−1.88) CDKN1A (+1.62) E2F2 (+2.20) E2F5 (−2.58) FNBP1 (−1.16) FOS (−1.95) FZD8 (+1.56) GNAQ (−1.28) HHAT (−1.64) ITGA2 (−2.48) MAP3K5 (−2.68) MDM2 (+1.77) MYC (−1.65) PRKAR2B (−1.53) PRKCA (−1.85) PRKCB (−1.55) PRKCE (−1.98) PRKCH (−1.69) PRKD (−1.73) TCF4 (−2.28) TGFB2 (+2.25) WNT6 (−1.83) |
BCL2L11 (−1.55) BMPR1B (−1.99) CAMK2D (−1.67) CDK6 (−1.79) CDKN1A (+1.45) E2F2 (+2.07) GNAQ (−1.15) HHAT (−1.57) MAP3K5 (−1.68) PRKCA (−1.73) PRKCE (−1.82) PRKCH (−1.55) PRKD1 (−1.64) TCF4 (−2.03) |
|
| Unfolded protein response | ||||
| p-value | 6.81e−5 | 1.32e−1 | 3.11e−1 | |
| Altered genes (fold change) | CEBPA (−1.71) DNAJB9 (+2.37) DNAJC3 (+1.56) HSPA5 (+1.52) HSPA6 (−1.65) XBP1 (+1.63) |
DNAJB9 (+2.02) HSPA6 (−1.54) MAP3K5 (−2.68) PPARG (−1.75) XBP1 (+1.55) |
CEBPA (+1.53) MAP3K5 (−1.68) |
|
| Cyclins and cell cycle regulation | ||||
| p-value | 2.64e−1 | 3.68e−2 | 2.14e−1 | |
| Altered genes (mean fold change) | E2F5 (−1.98) TGFB2 (+2.87) |
CCNE2 (+2.32) CDC25A (+1.82) CDK6 (−1.88) CDKN1A (+1.62) E2F2 (+2.20) E2F5 (−2.58) HDAC9 (−2.95) TGFB2 (+2.25) |
CDK6 (−1.79) CDKN1A (+1.45) E2F2 (+2.07) |
|
| Other significantly altered genes | ||||
| GPX5 (+2.14) |
BRCA2 (+1.68) E2F7 (+1.54) E2F8 (+1.80) EXO1 (+1.96) GPX5 (+2.50) MITF (−1.64) |
E2F8 (+1.80) EXO1 (+1.59) |
||
p-values indicate the statistical significance of the altered canonical pathway for each treatment group in comparison to the vehicle control (DMSO).